National Cancer Institute (nci)
Clinical trials sponsored by National Cancer Institute (nci), explained in plain language.
-
New transplant trial aims to cure Life-Threatening immune disorders
⭐️ CURE ⭐️ Recruiting nowThis study is testing whether a bone marrow or blood stem cell transplant from a healthy donor can cure people with severe primary immune deficiencies. The goal is to replace the patient's faulty immune system with a healthy one from a donor. Researchers are enrolling 354 patient…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: ⭐️ CURE ⭐️
Last updated Mar 30, 2026 14:29 UTC
-
New hope for a cure: replacing faulty immune systems
⭐️ CURE ⭐️ Recruiting nowThis study is testing whether a stem cell transplant can cure people with serious inherited immune system disorders. Doctors will give patients healthy stem cells from a donor to try to rebuild their immune system. The goal is to see if this procedure can successfully replace the…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: ⭐️ CURE ⭐️
Last updated Mar 24, 2026 12:01 UTC
-
Scientists test Next-Gen shot to block more Cancer-Causing viruses
⭐️ VACCINE ⭐️ Recruiting nowThis is an early-stage study to check the safety and immune response of a new vaccine called RG1-VLP. It aims to protect against additional types of human papillomavirus (HPV) that can cause cancer but aren't targeted by current vaccines like Gardasil-9. The trial will enroll 18 …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: ⭐️ VACCINE ⭐️
Last updated Mar 27, 2026 12:38 UTC
-
Precision radiation zaps prostate cancer in two sessions
Disease control Recruiting nowThis study is testing a new, highly focused radiation treatment for men with early-stage prostate cancer that is confined to one spot in the prostate. The goal is to see if delivering a high dose of radiation directly to the tumor in just two sessions can effectively control the …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 15:40 UTC
-
New drug trial targets precancerous tumors in genetic disorder
Disease control Recruiting nowThis study is testing a drug called abemaciclib for people with Neurofibromatosis type 1 (NF1) who have nerve tumors called atypical neurofibromas. The main goals are to find a safe dose of the drug and to see if it can shrink these tumors, which can sometimes turn into cancer. P…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
Scientists test powerful new drug duo to rally immune system against spreading cancers
Disease control Recruiting nowThis early-stage study is testing the safety of a new two-drug immunotherapy combination, with or without a precise form of radiation, for adults with advanced urinary tract cancers that have spread. The goal is to see if these treatments can work together to help the body's own …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New drug joins fight against tough head and neck cancers
Disease control Recruiting nowThis early-stage study is testing whether adding a new oral drug called ipatasertib to the standard treatment of chemotherapy plus radiation is safe and more effective for people with locally advanced head and neck cancer. The main goal is to find the safest and most effective do…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New 5-Drug combo trial aims to control Tough-to-Treat lymphomas
Disease control Recruiting nowThis study is testing the safety and effectiveness of a combination of five targeted drugs (called ViPOR) for adults whose B-cell lymphoma has come back or not improved after prior treatment. The goal is to see if this drug mix can control the cancer. Participants will receive th…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New cancer drug combo enters first human safety trial
Disease control Recruiting nowThis early-stage trial aims to find a safe and effective dose of a new drug, ZEN003694, when given with the standard chemotherapy capecitabine. It is for adults with advanced solid tumors (like colorectal cancer) that have spread or cannot be removed by surgery and have worsened …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for HIV patients battling aggressive lymphoma
Disease control Recruiting nowThis early-stage study is testing whether adding the drug pomalidomide to standard chemotherapy (with or without rituximab) is safe and tolerable for adults with HIV and aggressive B-cell lymphomas. The main goal is to find the highest dose that doesn't cause severe side effects.…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Gene therapy trial aims to turn Patients' own cells against rare, aggressive cancers
Disease control Recruiting nowThis early-stage trial is testing the safety of a new gene therapy for adults with certain T-cell lymphomas that have returned or not responded to prior treatments. Doctors will collect a patient's own immune cells, genetically modify them in a lab to target a protein (CCR4) foun…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for tough breast cancer: trial tests pill to boost standard treatment
Disease control Recruiting nowThis early-stage trial is testing the safety and best dose of a new oral drug, ASTX727, when added to standard chemotherapy and immunotherapy for patients with metastatic triple-negative breast cancer. The study aims to see if this combination can shrink or control tumors better …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New trial tests aggressive combo therapy to fight tough cervical cancers
Disease control Recruiting nowThis study is for people with cervical cancer that has spread to nearby tissues or lymph nodes. It compares two treatment plans that combine chemotherapy, radiation, and an immunotherapy drug called pembrolizumab. One plan adds extra chemotherapy and immunotherapy at the start. T…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug enters first human trial for Tough-to-Treat leukemias
Disease control Recruiting nowThis is a first-in-human study to find a safe dose and understand the side effects of an experimental drug called TAK-243. It is for adults with acute myeloid leukemia or myelodysplastic syndromes that have returned or not responded to prior treatments. The drug is given by IV an…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New 'Living Drug' trial targets tough cancers
Disease control Recruiting nowThis study is testing a new type of personalized cell therapy called TNhYP218 CAR T cells in adults with advanced solid tumors, including mesothelioma, that have come back or spread after standard treatment. Doctors take a participant's own immune cells, modify them in a lab to b…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug duo tested in fight against stubborn blood cancer
Disease control Recruiting nowThis early-stage study is testing the safety and best dose of a new two-drug combination for multiple myeloma that has come back or stopped responding to other treatments. The trial combines an oral pill (iberdomide) that targets cancer cell proteins with an injected immunotherap…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Scientists test re-engineered immune cells to fight tough cancers
Disease control Recruiting nowThis early-phase study is testing the safety of a new personalized treatment for advanced cancers, primarily liver cancer. Doctors take a patient's own immune cells, modify them in a lab to better target cancer, and infuse them back. The main goal is to see if this approach is sa…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New Three-Drug combo tested in fight against Tough-to-Treat leukemia
Disease control Recruiting nowThis study is for older adults or those too frail for intensive chemotherapy who have a newly diagnosed, specific type of acute myeloid leukemia (AML) with an FLT3 mutation. It aims to see if adding a third drug, gilteritinib, to the standard two-drug treatment (azacitidine and v…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New transplant strategy aims to cure cancers in HIV patients
Disease control Recruiting nowThis study is testing a new combination of drugs designed to prevent a dangerous complication called graft-versus-host disease (GVHD) after a bone marrow transplant. The goal is to see if this approach is safe and effective for people living with HIV who have blood cancers that c…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Targeted pill tested for Hard-to-Treat head cancers
Disease control Recruiting nowThis study is testing whether a daily pill called enasidenib can help control rare cancers in the nasal cavity and base of the skull. It is for adults whose cancer has a specific genetic change (IDH2 mutation) and has returned or spread after prior treatment. The goal is to see i…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
First-of-its-Kind immune cell therapy trial launches for kids with aggressive cancer
Disease control Recruiting nowThis early-stage study is testing a new type of personalized cell therapy for children and young adults whose rhabdomyosarcoma (a muscle cancer) has come back or hasn't responded to standard treatments. Doctors take a patient's own immune cells, modify them in a lab to better tar…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug duo targets genetic flaw in Tough-to-Treat liver cancer
Disease control Recruiting nowThis study is testing whether combining two drugs, sapanisertib and cabozantinib, works better than cabozantinib alone for people with advanced liver cancer that has a specific genetic mutation called β-catenin. The main goals are to find the safest dose of the combination and to…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Scientists test powerful Immune-Boosting combo against tough cancers
Disease control Recruiting nowThis study is testing whether combining two existing cancer drugs—pembrolizumab and aldesleukin—works better than either alone for adults with advanced melanoma or kidney cancer that has stopped responding to standard treatments. The goal is to see if this combination can shrink …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Scientists test novel drug duo in fight against Tough-to-Treat cancers
Disease control Recruiting nowThis early-phase study aims to find a safe and tolerable dose of a new drug combination for people with advanced breast cancer and other solid tumors that have a protein called HER2. The trial will test pidnarulex, which aims to stop tumor cell growth, together with an existing t…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New pill targets Cancer's weak spot: a hopeful trial for Tough-to-Treat tumors
Disease control Recruiting nowThis study is testing whether a pill called olaparib can help control advanced bladder and other urinary cancers that have specific DNA repair defects and have stopped responding to standard treatments like chemotherapy. The drug works by blocking a protein that helps cancer cell…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New combo trial aims to reawaken immune system against stubborn lymphomas
Disease control Recruiting nowThis early-stage study is testing the safety and best dose of a two-drug combination for people with B-cell lymphomas that have come back or stopped responding to other treatments. The treatment pairs an immunotherapy drug (nivolumab) with a pill (ASTX727) that may help the immun…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New hope for Tough-to-Treat leukemia: experimental pill joins fight
Disease control Recruiting nowThis early-stage study is testing a new oral drug, SNDX-5613, when given alongside standard chemotherapy for adults newly diagnosed with specific genetic types of acute myeloid leukemia (AML). The main goals are to find the safest and most effective dose of the new combination an…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Immune drug trial offers hope for Tough-to-Treat Virus-Linked cancers
Disease control Recruiting nowThis study is testing the drug nivolumab to see if it can slow or stop the growth of certain cancers linked to the Epstein-Barr virus (EBV). It is for people aged 12 and older with EBV-positive lymphomas or lymphoproliferative disorders who have no standard therapy options or who…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug trial targets Tough-to-Treat bile duct cancer
Disease control Recruiting nowThis study is testing a drug called tivozanib for people with advanced bile duct cancer (cholangiocarcinoma) that cannot be removed by surgery and has continued to grow after initial chemotherapy. The main goals are to find a safe dose and see if the drug can shrink or stop the g…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug duo aims to halt advanced cancers by targeting their genetic weaknesses
Disease control Recruiting nowThis study is testing whether a combination of two oral drugs, ZEN-3694 and talazoparib, can shrink or stop the growth of advanced solid tumors that have specific genetic features. It aims to enroll 88 adults whose cancer has progressed despite prior treatments. A key goal is to …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Scientists test Double-Duty immunotherapy to hold back aggressive head & neck cancer
Disease control Recruiting nowThis study is for adults whose nasopharyngeal cancer (a type of head and neck cancer linked to the Epstein-Barr virus) has returned or spread. After initial chemotherapy and immunotherapy, patients who are stable are randomly assigned to continue with standard immunotherapy alone…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New Triple-Threat treatment tested for aggressive blood cancer
Disease control Recruiting nowThis early-stage trial is testing whether combining three cancer drugs—iadademstat, venetoclax, and azacitidine—is safe and tolerable for adults with newly diagnosed acute myeloid leukemia (AML) who haven't received treatment yet. The study aims to find the best dose of this comb…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Scientists combine three weapons in fight against tough pancreatic cancer
Disease control Recruiting nowThis early-stage study aims to find a safe dose for a new combination treatment for pancreatic cancer that has grown locally but cannot be removed by surgery. The treatment combines a targeted drug (olaparib), an immunotherapy drug (durvalumab), and radiation therapy. The main go…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New hope for rare cancer patients as trial tests novel drug
Disease control Recruiting nowThis study is testing a new drug called PT-112 for people with advanced thymoma or thymic carcinoma, rare cancers that have returned or worsened after standard chemotherapy. The main goal is to see if the drug can shrink tumors. Participants will receive PT-112 by IV infusion in …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New Two-Drug attack on tough kidney cancers
Disease control Recruiting nowThis study is testing a new combination of two drugs, sasanlimab and palbociclib, for people with advanced kidney cancer. The goal is to find a safe and effective dose and to see if the treatment can shrink tumors. It is for adults with specific types of kidney cancer who have li…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Four-Drug attack on advanced colon cancer launches in new trial
Disease control Recruiting nowThis study is testing a new combination of four immunotherapy drugs for people with metastatic colorectal cancer that has spread and stopped responding to standard treatments. The goal is to see if this multi-drug approach can help the body's immune system fight the cancer more e…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New drug targets 'Undruggable' cancer driver in Tough-to-Treat lymphomas
Disease control Recruiting nowThis early-stage trial is testing a new drug called pidnarulex (CX-5461) in adults with aggressive, hard-to-treat B-cell lymphomas that have a specific genetic feature called MYC aberration. The main goals are to find the safest and most effective dose and to see if the drug can …
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New Two-Drug attack on rare blood cancer shows promise
Disease control Recruiting nowThis study is testing if adding a new drug, enasidenib, to a standard treatment works better for controlling a high-risk type of myelodysplastic syndrome (MDS), a bone marrow disorder. It will involve about 54 adults with a specific genetic change (IDH2 mutation) who have not had…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Immune-Boosting shot tested for HIV-Related cancer
Disease control Recruiting nowThis study is testing whether a lab-made protein called CYT107 can shrink Kaposi sarcoma tumors in people living with HIV. Participants receive weekly injections for four weeks to see if boosting their immune system helps fight the cancer. The goal is to see if this approach can …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New combo attack on rare pancreatic cancer
Disease control Recruiting nowThis early-stage trial is testing the safety and best dose of combining two targeted cancer drugs for people with advanced pancreatic neuroendocrine tumors (PNETs). One drug blocks signals that help tumors grow, while the other delivers radiation directly to cancer cells. Researc…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Major trial tests Four-Drug combo against Tough-to-Treat uterine cancer
Disease control Recruiting nowThis large, late-stage trial is comparing three different drug combinations for treating advanced or recurrent endometrial (uterine) cancer that has specific genetic features. It aims to see if adding a drug called bevacizumab to standard chemotherapy and immunotherapy helps pati…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New pill tested to tame deadly Virus-Linked inflammation
Disease control Recruiting nowThis study is testing an oral drug called pacritinib for two rare, severe inflammatory diseases caused by the Kaposi sarcoma herpesvirus (KSHV) in people living with HIV. Up to 75 adults with either KSHV-associated multicentric Castleman disease (MCD) or KSHV inflammatory cytokin…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope for fighting back when brain cancer returns
Disease control Recruiting nowThis study aims to find a safe and effective schedule for delivering a second round of radiation to treat glioblastoma brain tumors that have returned after initial treatment. It will enroll 28 adults whose cancer has come back, testing radiation given four times a week for one, …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC
-
New drug combo aims to halt tough pancreatic cancer
Disease control Recruiting nowThis study is testing if adding an experimental pill called M3814 to a short, intense course of radiation therapy is safe and more effective than radiation alone for people with locally advanced pancreatic cancer. The goal is to better control the cancer and stop it from growing …
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC
-
Head-to-Head trial tests promising new drug combo for rare blood cancer
Disease control Recruiting nowThis study is comparing two different drug combination strategies for people newly diagnosed with a rare, slow-growing blood cancer called Waldenström's macroglobulinemia. About 92 participants will be randomly assigned to receive either a combination of ibrutinib and rituximab (…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Blood test could revolutionize Post-Surgery cancer care
Disease control Recruiting nowThis large trial is testing if a simple blood test can better identify which patients need extra treatment after surgery for aggressive urinary tract cancers. The test looks for tiny traces of cancer DNA in the blood. Patients are then assigned to receive either one or two immuno…
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Targeted pill tested to control recurrent brain tumors
Disease control Recruiting nowThis study is testing whether a pill called erdafitinib can help control a specific type of recurrent brain tumor (glioma) that has a particular genetic change. It is for adults whose tumors have grown back or worsened after initial treatment. The drug aims to block a faulty prot…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New heat beam targets prostate cancer, aims to spare side effects
Disease control Recruiting nowThis study is testing a new, focused treatment for prostate cancer that uses heat from an ultrasound device to destroy tumors. The procedure is guided by MRI imaging to precisely target the cancer. The goal is to control the disease while potentially avoiding the common side effe…
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Head-to-Head trial tests new drug against standard for rare lymphoma
Disease control Recruiting nowThis study is testing whether a newer drug called mosunetuzumab is better than the standard drug rituximab at keeping a rare, slow-growing lymphoma from getting worse. About 70 adults with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) will be randomly assigned to receiv…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Dual attack: fighting cancer while protecting a transplanted kidney
Disease control Recruiting nowThis study is testing a new treatment approach for people who have had a kidney transplant and now have advanced skin cancer that cannot be removed by surgery or has spread. The goal is to see if a combination of cancer immunotherapy drugs (nivolumab and ipilimumab) can be given …
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New Two-Drug combo aims to tame tough leukemia relapse in kids
Disease control Recruiting nowThis study is testing if adding the drug nivolumab to a standard immunotherapy (blinatumomab) works better for controlling B-cell acute lymphoblastic leukemia (B-ALL) that has come back after initial treatment. It is for children and young adults aged 1 to 31 who have had their f…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Scientists test 'Mini-Tumors' to find best heated chemo for tough cancers
Disease control Recruiting nowThis study aims to improve a treatment for cancers that have spread to the lining of the abdomen. The treatment involves surgery to remove visible tumors, followed by a wash of heated chemotherapy inside the abdomen. Researchers want to see if testing tumor samples in special lab…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Scientists test Custom-Made vaccine to fight spreading breast cancer
Disease control Recruiting nowThis study is testing whether adding a personalized vaccine to standard immunotherapy and chemotherapy helps control advanced triple-negative breast cancer that has spread. It will compare two groups of about 70 patients total: one gets the vaccine plus standard drugs, the other …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New hope for Tough-to-Treat cancer: adding immune booster to standard chemo
Disease control Recruiting nowThis study is testing if adding an immunotherapy drug called atezolizumab to standard chemotherapy works better for controlling a rare and aggressive type of cancer that starts outside the lungs. It will involve about 189 adults whose cancer has spread and cannot be removed by su…
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New 'Alpha' radiation therapy tested for Tough-to-Treat cancers
Disease control Recruiting nowThis study is testing a new targeted radiation drug for adults whose gastrointestinal neuroendocrine tumors (GI NET) or adrenal tumors (pheochromocytoma/paragangliomas) have spread and cannot be removed by surgery, and have already been treated with a similar type of radiation th…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New hope for rare cancer: radiation before surgery trial seeks to stop recurrence
Disease control Recruiting nowThis study is testing if giving targeted radiation therapy before surgery is safe and can help control a rare and aggressive adrenal gland cancer that has come back after initial treatment. It will enroll up to 32 adults whose recurrent cancer can still be surgically removed. The…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Major trial uses genetic blueprint to find the right drug combo for advanced cancer
Disease control Recruiting nowThis trial is a large screening program that matches patients with advanced solid tumors to one of many smaller treatment studies. It uses genetic testing on a patient's tumor to find specific mutations. Patients are then assigned to a drug combination designed to target those mu…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Radical transplant trial offers hope for devastating new disease
Disease control Recruiting nowThis study is testing whether a stem cell transplant from a donor can control VEXAS syndrome, a serious and often treatment-resistant disease that causes severe inflammation and blood problems. Researchers will give 54 adults with severe VEXAS a transplant after using medications…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Major trial aims to boost survival for young bone cancer patients
Disease control Recruiting nowThis large study is testing if adding a newer drug called cabozantinib to standard chemotherapy works better for treating newly diagnosed osteosarcoma, a type of bone cancer. It will involve over 1,100 patients under 40 years old, comparing the new combination against standard ch…
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Scientists test One-Two punch against deadly blood cancers
Disease control Recruiting nowThis study is testing a new approach for adults with aggressive blood cancers that are hard to cure. It combines two powerful treatments—a bone marrow transplant from a partially matched donor and genetically modified immune cells (CAR-T cells)—given at the same time. The goal is…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New hope for tough liver cancer: boosting chemo before surgery
Disease control Recruiting nowThis study is testing if adding an immunotherapy drug called durvalumab to standard chemotherapy before surgery helps people with a high-risk type of liver cancer called cholangiocarcinoma. The goal is to shrink the tumor before the operation, potentially making surgery more succ…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Scientists test new drug duo to fight Virus-Driven cancers
Disease control Recruiting nowThis early-stage study aims to find a safe dose of two drugs, pomalidomide and nivolumab, for adults whose cancers are caused by viruses. It is for people with cancers like Kaposi sarcoma, certain lymphomas, and HPV-linked cancers that have not responded to standard treatments. T…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Could inhaled antibiotics boost lung cancer treatment? new trial investigates
Disease control Recruiting nowThis early-phase study is testing whether adding two inhaled antibiotics to a standard immunotherapy drug (pembrolizumab) is safe and feasible for people with advanced non-small cell lung cancer. The idea is that bacteria in the lungs might help tumors grow, and treating these ba…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Major trial aims to boost survival for kids with tough cancer
Disease control Recruiting nowThis study is testing if adding a drug called dinutuximab to the first stage of treatment helps children with newly diagnosed high-risk neuroblastoma. Dinutuximab is an immunotherapy that helps the body's own immune system find and kill cancer cells. The trial will compare the cu…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New pill trial targets Tough-to-Treat lung cancer mutation
Disease control Recruiting nowThis study is testing if a daily pill called osimertinib can help control advanced non-small cell lung cancer that has a specific genetic change called an EGFR exon 20 insertion. It is for adults whose cancer has worsened after at least one prior treatment. The main goal is to se…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New drug duo aims to outsmart tough cancers that resist standard treatment
Disease control Recruiting nowThis study is testing whether combining two drugs, cabozantinib and nivolumab, can help control advanced melanoma or head and neck cancer that has worsened despite standard immunotherapy. It will enroll about 150 adults whose cancer has progressed on prior treatment. A key goal i…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Scientists Re-Engineer Patients' own cells to hunt blood cancer
Disease control Recruiting nowThis study is testing a personalized cell therapy for adults with advanced B-cell leukemias that have not responded to standard drugs. Doctors take a patient's own immune cells, modify them in a lab to target a protein (CD19) found on their cancer cells, and then infuse them back…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New Two-Drug attack tested for Tough-to-Treat sarcomas
Disease control Recruiting nowThis study is testing a new treatment approach for people with advanced soft tissue sarcomas, including leiomyosarcoma and dedifferentiated liposarcoma. It aims to find the safest dose and best schedule for combining the drug abemaciclib with chemotherapy (gemcitabine). The main …
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New pill trial targets Tough-to-Treat blood cancer comeback
Disease control Recruiting nowThis study is testing whether a pill called venetoclax can help control hairy cell leukemia that has come back after previous treatments. About 20 adults whose cancer has relapsed will take the daily pill for up to 19 months. Researchers want to see if the treatment shrinks the c…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
First human trial tests new drug duo against aggressive cancers
Disease control Recruiting nowThis early-stage study aims to find the safest dose of two oral drugs—ZEN003694 and abemaciclib—when given together to patients with advanced cancers that have spread or cannot be removed by surgery. The trial will enroll about 45 adults and teens (12+) with specific cancers, inc…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New hope for Tough-to-Treat blood cancer
Disease control Recruiting nowThis study is testing a new two-drug combination (tovorafenib + rituximab) for hairy cell leukemia that has come back or hasn't responded to prior treatment. It will also compare this new combo to the current standard treatment (cladribine + rituximab) for patients who haven't st…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New drug combo trial aims to tame aggressive blood cancers
Disease control Recruiting nowThis study is testing whether adding a new drug called iadademstat to an existing treatment (ASTX727) works better for controlling advanced blood cancers. It will involve about 62 adults with specific aggressive forms of myeloproliferative neoplasms (MPNs) that have progressed. T…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Scientists test new drug duo to attack tough cancers
Disease control Recruiting nowThis early-stage study is testing a new combination of two drugs, DS-8201a and olaparib, for people with advanced cancers that have a protein called HER2. The main goal is to find the safest and most effective dose. Researchers will also check if the treatment helps shrink or con…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Major trial tests new weapons against aggressive head and neck cancers
Disease control Recruiting nowThis study is for patients who have had surgery for high-risk head and neck cancer. It aims to find the best combination of radiation and drugs to prevent the cancer from coming back. Researchers are comparing the standard treatment (radiation with cisplatin) to two newer approac…
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New drug combo aims to outsmart tough cancers
Disease control Recruiting nowThis study is for people with advanced HER2-positive cancers that have come back or spread. It aims to see if taking two targeted drugs together works better than taking one alone to slow or stop cancer growth. About 70 participants will be randomly assigned to one of the two tre…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New vaccine could spare throat cancer patients from radiation
Disease control Recruiting nowThis study is testing if adding an experimental vaccine (PRGN-2009) to standard chemotherapy can effectively treat newly diagnosed HPV-linked throat cancer. The goal is to see if this combination can control the cancer so well that patients can avoid radiation therapy, which ofte…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Second shot at radiation therapy tested for returning gut tumors
Disease control Recruiting nowThis study is for adults with advanced neuroendocrine tumors in the digestive system that have spread and cannot be removed by surgery, and which have started growing again after a previous successful round of a targeted radiation therapy. It aims to see if giving a second round …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New drug combo aims to supercharge immune system to fight cancer before surgery
Disease control Recruiting nowThis study is testing if adding a new immune-boosting drug (CDX-1140) to an existing immunotherapy (cemiplimab) works better before surgery for advanced head and neck cancer. The goal is to shrink the tumor more effectively, which could lead to less extensive surgery. About 44 pa…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Early immune boost after transplant aims to stop blood Cancer's return
Disease control Recruiting nowThis study is testing whether giving an extra infusion of donor immune cells one week after a bone marrow transplant can help prevent the cancer from returning in people with high-risk blood cancers like leukemia and lymphoma. Researchers want to find the safest dose of these cel…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New hope for tough blood cancers: trial tests promising pill
Disease control Recruiting nowThis study is testing an oral drug called pacritinib for people aged 12 and older with myelodysplastic syndromes (MDS), a group of serious blood and bone marrow disorders. The first part aims to find a safe dose for teenagers, and the second part will see how well the drug works …
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New hope for Tough-to-Treat cancers: adding immune booster to standard care
Disease control Recruiting nowThis study is for people with advanced stomach or esophageal cancer that has worsened after initial treatment. It tests if adding an immunotherapy drug called nivolumab to the standard two-drug chemotherapy helps control the cancer better and helps patients live longer. About 224…
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New immune drug targets liver tumors in advanced cancer trial
Disease control Recruiting nowThis study is testing whether adding a new immune-stimulating drug called PDS01ADC to a specialized liver cancer treatment can better control advanced cancers that have spread to the liver. The treatment involves surgically placing a pump that delivers chemotherapy directly to th…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New pill vs. standard IV chemo: major trial for Kids' brain tumors
Disease control Recruiting nowThis study is for children and young adults (ages 2-21) with a specific type of slow-growing brain tumor called low-grade glioma. It compares a newer oral drug, selumetinib, to the current standard intravenous chemotherapy (carboplatin and vincristine). The main goal is to see if…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New Bladder-Saving combo could spare cancer patients major surgery
Disease control Recruiting nowThis study is testing whether a combination of radiation therapy and an immunotherapy drug (pembrolizumab) can help patients with muscle-invasive bladder cancer avoid having their bladder surgically removed. It is for patients whose tumors have shrunk significantly after initial …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New drug trial targets Tough-to-Treat blood cancer after other treatments fail
Disease control Recruiting nowThis study is testing an oral drug called mirdametinib for adults with chronic lymphocytic leukemia (CLL) or a related lymphoma that has returned or stopped responding to standard treatments. The drug aims to block a specific signal that tells cancer cells to grow, potentially sl…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Two drugs vs. one: new hope for Tough-to-Treat uterine cancer
Disease control Recruiting nowThis study is for people whose endometrial (uterine) cancer has returned after treatment. It compares two different immunotherapy approaches to see which is better at controlling the cancer. One group gets a single immunotherapy drug (nivolumab), while the other gets a combinatio…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New hope for babies: testing powerful drug combos against rare leukemia
Disease control Recruiting nowThis study is testing whether adding two newer drugs, blinatumomab and venetoclax, to standard chemotherapy works better for babies under one year old with a rare and aggressive type of blood cancer called acute lymphoblastic leukemia (ALL). The main goal is to see if these combi…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Can a year of treatment stop lung cancer from coming back?
Disease control Recruiting nowThis study is for people with early-stage non-small cell lung cancer who have had surgery and whose initial treatment completely removed the cancer. It compares two approaches: one group receives a year of immunotherapy (durvalumab) to try to prevent the cancer from returning, wh…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Scientists test powerful new drug cocktail against deadly bile duct cancer
Disease control Recruiting nowThis study is testing a new four-drug combination for adults with advanced bile duct cancer that has worsened after initial treatment. The goal is to see if adding a new immunotherapy drug (CDX-1140) to standard chemotherapy and another immunotherapy (Keytruda) can better control…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Targeted radiation vs. standard pill: new hope for advanced lung carcinoid tumors
Disease control Recruiting nowThis study is testing whether a new targeted radiation treatment is better than a standard pill at controlling advanced lung neuroendocrine tumors (also called carcinoid tumors). The new treatment, called lutetium Lu 177 dotatate, is an IV drug that seeks out and delivers radiati…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New hope for lymphoma patients who failed CAR T-Cell treatment
Disease control Recruiting nowThis study tests whether a two-drug combination can help patients with mantle cell lymphoma whose cancer has returned or stopped responding after they received CAR T-cell therapy. The treatment uses glofitamab, which helps the immune system target cancer cells, along with obinutu…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New trial tests if switching PARP inhibitors can help control advanced cancers
Disease control Recruiting nowThis study is testing whether the drug talazoparib can help control advanced cancers in patients whose tumors have specific mutations in genes that help repair DNA damage. It is enrolling 36 adults with various advanced solid tumors (like breast, ovarian, prostate, pancreatic, an…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Scientists attack 'Resistant' bladder cancer with new drug duo
Disease control Recruiting nowThis early-stage study is testing a new two-drug combination for people with advanced bladder cancer that has spread and is no longer responding to standard immunotherapy. The goal is to see if adding a new pill called emavusertib (CA-4948) to the existing drug pembrolizumab is s…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Pioneering trial tests cancer drug on patients with 'Double Trouble' autoimmune conditions
Disease control Recruiting nowThis study is testing the safety and effects of the immunotherapy drug nivolumab in people who have both advanced cancer and an autoimmune disease like lupus, rheumatoid arthritis, or Crohn's disease. It will enroll 300 adults to see if the drug can help control their cancer whil…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New drug duo targets Tough-to-Treat cancers
Disease control Recruiting nowThis study is testing the safety and effectiveness of a new two-drug combination for people with advanced solid tumors, including pancreatic cancer, that have spread or stopped responding to standard treatments. The trial aims to find the best dose and see if the drugs can help c…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New combo therapy aims to keep recurrent prostate cancer at bay
Disease control Recruiting nowThis study is testing whether adding an immunotherapy injection (PDS01ADC) to a standard prostate cancer pill (enzalutamide) works better than the pill alone for men whose cancer has returned after initial treatment. The goal is to control the cancer and delay its progression for…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Scientists test powerful immune cell combo to shrink tumors before surgery
Disease control Recruiting nowThis study is testing whether a new combination of immune-boosting drugs, with or without special lab-made immune cells, can shrink head and neck tumors before surgery. It is for adults with a specific type of cancer not caused by HPV who are scheduled for tumor removal. The goal…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Scientists test 'One-Two Punch' against Tough-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing the safety and best dose of a new two-drug combination for people with advanced solid tumors that have a specific marker called HER2. The treatment pairs an existing targeted cancer drug with a new pill that aims to block cancer cells' ability to…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New cancer combo trial aims to boost immune attack on tumors
Disease control Recruiting nowThis study is testing whether adding an immunotherapy drug called durvalumab to standard chemotherapy is safe and can help the immune system better fight cancer. It is for adults with advanced solid tumors that have spread or cannot be removed by surgery. Researchers will monitor…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Tailored attack on HIV-Linked anal cancer tests gentler vs. stronger approach
Disease control Recruiting nowThis study is testing two personalized treatment plans for anal cancer in people living with HIV. For patients with low-risk cancer, researchers are testing a reduced dose of chemotherapy and radiation to see if it's effective with fewer side effects. For patients with high-risk …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New hope for Tough-to-Treat cancers: experimental drug trial targets rare lymphomas
Disease control Recruiting nowThis study is testing an experimental drug called daratumumab for people with rare, aggressive types of lymphoma that have come back or haven't responded to standard treatments. The drug is given as a simple injection under the skin. Researchers want to see if it can help control…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Scientists test 'Super Cocktail' to fight stubborn blood cancer
Disease control Recruiting nowThis early-stage study is testing a new combination of six different targeted drugs for adults whose B-cell lymphoma has come back or hasn't responded to previous treatment. The main goal is to find the safest dose of this combination and see if it can help control the cancer. Re…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New pill targets aggressive, returning brain cancer
Disease control Recruiting nowThis study is testing an oral drug called zotiraciclib for people whose aggressive brain tumors (gliomas) have come back after prior treatment. It is specifically for patients whose tumors have certain genetic changes (IDH1 or IDH2 mutations). The main goals are to find a safe do…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
New hope for Tough-to-Treat head & neck cancer recurrence
Disease control Recruiting nowThis study is for people whose head and neck cancer has come back after initial treatment. After surgery, it compares a newer immunotherapy drug (pembrolizumab) to the standard combination of chemotherapy and radiation. The main goal is to see if the immunotherapy helps patients …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Major cancer trial aims to boost survival for Tough-to-Treat tumors
Disease control Recruiting nowThis large, late-stage trial is testing whether adding an immunotherapy drug (pembrolizumab) to standard chemotherapy (doxorubicin) works better than chemotherapy alone for people with advanced or inoperable sarcomas. The goal is to see if the combination helps patients live long…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New cancer drug trial seeks to control advanced tumors
Disease control Recruiting nowThis early-stage trial is testing a new drug called CBX-12 in patients with advanced solid tumors that have spread to other parts of the body. The drug works by damaging cancer cell DNA to kill tumors. Researchers will study how the drug affects cancer cells, measure tumor respon…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New hope for rare, aggressive cancers as national trial tests promising drug duo
Disease control Recruiting nowThis study is testing whether two existing cancer drugs, sacituzumab govitecan and atezolizumab, can help control rare and aggressive cancers of the bladder, urinary tract, kidney, and penis. The trial will enroll 60 adults to receive one or both drugs, given through an IV, to se…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New hope for Tough-to-Treat throat cancer: three drugs vs. two
Disease control Recruiting nowThis study is for people with advanced nasopharyngeal cancer (a type of throat cancer) that has spread or returned after standard treatments. It will test if adding a pill called cabozantinib to two immunotherapy drugs (nivolumab and ipilimumab) works better than the two immunoth…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New hope for rare, aggressive cancer: experimental drug combo enters human trials
Disease control Recruiting nowThis study is testing a new oral drug, ZEN003694, in combination with standard chemotherapy for people with advanced NUT carcinoma, a rare and aggressive cancer. The main goals are to find a safe dose of the combination and see if it helps shrink tumors or slow the cancer's growt…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New hope for rare cancers: testing approved drugs on tough tumors
Disease control Recruiting nowThis study is testing whether a combination of two drugs, already approved for some common bladder cancers, can help control rare types of urinary tract and testicular cancers. It will involve about 68 adults whose cancer has spread and who have few other treatment options. The g…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Race against time: can treating cancer before symptoms appear save lives?
Disease control Recruiting nowThis study is testing whether starting a two-drug cancer treatment early, before patients have any symptoms, leads to better survival for people with high-risk chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It will compare starting treatment immediately v…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Double attack on tough lung cancer: radiation joins forces with immune therapy
Disease control Recruiting nowThis study is for people with extensive-stage small cell lung cancer that has spread. It tests if adding a targeted course of radiation therapy to ongoing immunotherapy (atezolizumab) can keep the cancer from growing or spreading for a longer time compared to continuing immunothe…
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Two drugs vs. one: major trial aims to extend life for advanced lung cancer patients
Disease control Recruiting nowThis study is for people with a specific type of advanced lung cancer that has spread and has an EGFR gene change. It compares a standard drug (osimertinib) alone against that same drug combined with a second drug (bevacizumab). The goal is to see if the two-drug combination can …
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New drug aims to halt Cancer's deadly spread in first human test
Disease control Recruiting nowThis is the first-ever study in people of an experimental drug called metarrestin. The main goals are to find a safe dose and see if it can shrink tumors. It is for adults and teenagers (12+) with advanced solid tumors that have spread and have not been cured by standard treatmen…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Radioactive drug trial offers hope for rare, untreatable tumors
Disease control Recruiting nowThis study is testing an experimental radioactive drug called Lu-177-DOTATATE for adults with rare adrenal or nerve-related tumors that cannot be removed by surgery. The main goals are to see if the treatment is safe and if it can help patients live longer without their cancer ge…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New drug aims to boost cancer treatment effectiveness
Disease control Recruiting nowThis study is testing whether adding an experimental drug called TRC102 to standard treatment helps people with stage III non-squamous non-small cell lung cancer live longer without their cancer getting worse. About 42 participants will receive either the standard treatment (chem…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Fighting cancer with your own supercharged immune cells
Disease control Recruiting nowThis study is testing an experimental cell therapy for people with metastatic melanoma that has spread. Doctors take a patient's own immune cells from a tumor, grow billions of them in a lab, and infuse them back to attack the cancer. The trial is also testing if adding the drug …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New drug combo tested to control Tough-to-Treat gynecologic cancers
Disease control Recruiting nowThis study is for women whose ovarian or endometrial cancer has returned or persisted despite prior treatment and has a specific genetic change (a RAS pathway mutation). It aims to see if taking two targeted drugs (selumetinib and olaparib) together works better than taking just …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Scientists train Patients' own cells to fight metastatic cancer
Disease control Recruiting nowThis study tests whether a patient's own immune cells, removed from their tumor and multiplied in a lab, can shrink tumors when given back alongside the drug pembrolizumab. It's for adults with advanced digestive tract, breast, ovarian, or other cancers that have spread and stopp…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New Two-Punch combo tested for Tough-to-Treat ovarian cancer
Disease control Recruiting nowThis early-phase study is testing the safety and best dose of two oral drugs, abemaciclib and olaparib, given together for ovarian cancer that has returned and is resistant to standard platinum-based chemotherapy. The goal is to see if combining these drugs, which work in differe…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New Triple-Threat attack on advanced prostate cancer
Disease control Recruiting nowThis study is testing whether combining a bone-targeting radiation drug with one or two other medications works better for advanced prostate cancer that has spread to bones and stopped responding to standard hormone therapy. It will compare three approaches: the radiation drug al…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Cancer trial tests 'Less is More' approach to powerful drug
Disease control Recruiting nowThis study is testing a new method for giving the cancer drug atezolizumab. Researchers want to see if they can use lower doses, given less often, by carefully monitoring drug levels in a patient's blood. The goal is to see if this personalized approach can still control the canc…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New hope for rare cancers: national trial tests promising drug duo
Disease control Recruiting nowThis study is testing whether a combination of two existing cancer drugs, nilotinib and paclitaxel, can help control rare cancers that have stopped responding to standard treatments. It is for adults with specific rare, advanced solid tumors, including certain ovarian cancers, an…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Doctors train Patients' own cells to fight lung cancer in new trial
Disease control Recruiting nowThis study is testing a personalized cell therapy for adults with advanced non-small cell lung cancer that has stopped responding to standard treatments. Doctors remove a patient's tumor, grow special immune cells from it in a lab, and then infuse a large number of these 'tumor-f…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Boosting the Body's defenses: can immunotherapy help shrink tumors before surgery?
Disease control Recruiting nowThis study is for people with high-grade cancer in their upper urinary tract (kidney or ureter). It compares two approaches before surgery: standard chemotherapy alone versus chemotherapy plus an immunotherapy drug called durvalumab. The goal is to see if adding durvalumab helps …
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Major trial aims to stop lung Cancer's return after surgery
Disease control Recruiting nowThis large, late-stage trial is testing if adding an immunotherapy drug (pembrolizumab) to standard chemotherapy helps patients live longer without their cancer returning. It is for people with stage II or III non-small cell lung cancer who have already had their tumor surgically…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New Drug-Radiation combo tested for aggressive brain cancers that return
Disease control Recruiting nowThis early-stage trial is testing whether combining an experimental drug called triapine with radiation therapy is safe for adults with glioblastoma or astrocytoma brain tumors that have returned after previous treatment. The study aims to find the highest dose of triapine that c…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Major trial aims to stop High-Risk breast cancer from coming back
Disease control Recruiting nowThis large, late-stage trial is testing if adding an immunotherapy drug called durvalumab to standard chemotherapy is better than chemotherapy alone for preventing cancer from returning. It is for adults with a specific high-risk type of breast cancer that is hormone-positive and…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Scientists test Triple-Threat attack on tough breast cancer
Disease control Recruiting nowThis early-stage trial is testing the safety of a new three-drug combination for people with advanced triple-negative breast cancer. It combines a new experimental pill (ZEN003694) with an immunotherapy drug (pembrolizumab) and a standard chemotherapy (nab-paclitaxel). The main g…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New hope for cancers that resist standard treatments
Disease control Recruiting nowThis study is testing whether combining two drugs can help people with aggressive cancers that have stopped responding to standard treatments. It focuses on small cell lung cancer and other cancers with specific genetic weaknesses that have become resistant to previous drugs. The…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New hope for slowing advanced prostate cancer
Disease control Recruiting nowThis study is testing whether adding an experimental immunotherapy drug called PDS01ADC to standard chemotherapy (docetaxel) is safe and can help men whose prostate cancer has spread. It is for men with two types of advanced prostate cancer: one that still responds to hormone the…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
First-of-its-Kind immune cell therapy trial launches for Tough-to-Treat blood cancer
Disease control Recruiting nowThis study is testing the safety and early effects of a new treatment called anti-CD22 CAR T-cell therapy for adults with hairy cell leukemia that has come back or not responded to other standard treatments. Doctors will collect a patient's own immune cells, modify them in a lab …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
First patients sought for groundbreaking trial targeting rare, aggressive cancers
Disease control Recruiting nowThis is the first-ever study in people for a new drug called ADCT-701, designed for adults with rare and hard-to-treat cancers like neuroendocrine tumors and malignant peripheral nerve sheath tumors. The main goal is to find the safest and most effective dose by giving the drug t…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Scientists train Patients' own cells to hunt blood cancer
Disease control Recruiting nowThis early-stage study is testing a new, personalized treatment for several types of blood cancer that are hard to treat. Doctors take a patient's own immune cells (T cells), genetically modify them in a lab to recognize and attack their specific cancer, and then infuse them back…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
Targeted drug trial aims to keep pancreatic cancer from coming back
Disease control Recruiting nowThis study is testing if adding the drug olaparib after surgery and chemotherapy can help prevent pancreatic cancer from returning. It is for patients whose cancer has been surgically removed and who have specific genetic mutations (BRCA1, BRCA2, or PALB2). Participants will take…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
New hope for tough pancreatic cancers: experimental drug combo enters human testing
Disease control Recruiting nowThis early-stage trial is testing whether adding a new oral drug called CA-4948 to standard chemotherapy is safe and tolerable for people with advanced pancreatic cancer that has spread or cannot be removed by surgery. The main goal is to find the highest dose that patients can h…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
Radioactive drug combo aims to zap rare gut tumors
Disease control Recruiting nowThis study is testing whether combining two drugs, Lutathera and Olaparib, can shrink rare neuroendocrine tumors in the digestive system or pancreas that cannot be removed by surgery. About 56 adults will receive Lutathera through an IV every 8 weeks and take Olaparib pills twice…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
Head-to-Head cancer drug showdown: can new treatment outperform standard?
Disease control Recruiting nowThis large study compares two antibody treatments for people with early-stage follicular lymphoma, a slow-growing blood cancer. Researchers want to see if a newer drug called mosunetuzumab keeps the cancer under control longer than the standard treatment rituximab. The trial will…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
Early trial tests old antibiotic as new weapon against tough cancers
Disease control Recruiting nowThis is an early safety study testing a drug called novobiocin in people with advanced solid tumors that have specific mutations affecting DNA repair. The main goal is to find the safest dose and understand the side effects. Researchers hope the drug will block a cancer cell's ba…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New transplant strategy aims to tame tough blood cancer
Disease control Recruiting nowThis study is testing a stem cell transplant to try to cure or control a rare and aggressive type of blood cancer called peripheral T-cell lymphoma. It is for patients aged 12 and older whose cancer has not responded to standard treatments. Researchers are also testing different …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Major trial aims to replace harsh chemo with targeted immunotherapy for hodgkin lymphoma
Disease control Recruiting nowThis large, late-stage trial is comparing a new immunotherapy approach to standard chemotherapy for children and adults with early-stage Hodgkin lymphoma. The goal is to see if the immunotherapy combination (brentuximab vedotin and nivolumab) can help patients live longer without…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Scientists test 'Double Punch' drug combo for Tough-to-Treat stomach cancers
Disease control Recruiting nowThis early-stage study is testing the safety and best dose of a new two-drug combination for people with advanced cancers that have a specific marker called HER2. The trial focuses on stomach and gastroesophageal junction cancers that have spread or cannot be removed by surgery, …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New hope for rare cancers: Triple-Threat therapy trial opens
Disease control Recruiting nowThis study is testing a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—for patients with rare types of bladder, kidney, penile, and other urinary tract cancers that have spread. The goal is to see if this three-drug approach can shrink tumors and control the d…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
New drug combo aims to keep aggressive lung cancer at bay
Disease control Recruiting nowThis study is for people with extensive-stage small cell lung cancer that has spread. It tests whether adding a new oral drug called iadademstat to standard immunotherapy maintenance treatment can help control the cancer and prevent it from growing for a longer period. The first …
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
Could a lower dose of a harsh transplant drug be the key to fewer complications?
Disease control Recruiting nowThis study aims to find the lowest effective dose of a drug called cyclophosphamide, given after a stem cell transplant, to prevent a serious complication called graft-versus-host disease (GVHD). The goal is to reduce the drug's own side effects while still protecting patients. I…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
New hope for kids with Tough-to-Treat cancer
Disease control Recruiting nowThis study is testing a new drug, rhIL-15, combined with three standard cancer drugs, to see if it is safe and can help control neuroblastoma. It is for children and young adults (ages 3-35) whose cancer has come back or hasn't responded to other treatments. The main goal is to f…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:29 UTC
-
Gentler transplant approach aims to help frail patients beat blood cancers
Disease control Recruiting nowThis study is testing if using a lower dose of a key drug (cyclophosphamide) after a bone marrow transplant can reduce side effects while still preventing a dangerous complication where donor cells attack the body. It focuses on older adults or those less fit for standard transpl…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New hope for transplant patients battling debilitating immune reaction
Disease control Recruiting nowThis study is testing an oral drug called pacritinib for people with chronic graft-versus-host disease (cGVHD) that hasn't improved after at least two other treatments. cGVHD is a serious immune system complication that can occur after a stem cell transplant. The trial aims to se…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New drug trial targets advanced cancers that have spread
Disease control Recruiting nowThis is an early-stage study testing a new oral drug called pidnarulex in patients with advanced solid tumors that have spread. The main goals are to see how safe the drug is, find the right dose, and understand how it affects cancer cells. Researchers will also check if the drug…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New hope for Tough-to-Treat colon cancer patients
Disease control Recruiting nowThis early-stage trial is testing whether combining two cancer drugs—abemaciclib and 5-fluorouracil—is safe and tolerable for people with advanced colorectal cancer that has spread and stopped responding to standard treatments. Researchers will enroll 39 adults to find the best d…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
Can a natural supplement help fight prostate cancer before surgery?
Disease control Recruiting nowThis study is testing whether a dietary supplement called Urolithin A can help reduce cellular stress in prostate cancer tumors. It involves 90 men with prostate cancer who are scheduled for surgery to remove their prostate. Participants will take either the supplement or a place…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New drug duo aims to outsmart tough cancers
Disease control Recruiting nowThis study is testing if adding a second drug (panitumumab) to a targeted cancer pill (sotorasib) works better than the pill alone for patients with advanced solid tumors that have a specific KRAS G12C mutation. It is for people whose cancer has spread and who have already tried …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New hope for tough blood cancers: first human trial begins
Disease control Recruiting nowThis is a first-in-human study to find a safe dose of a new drug called cirtuvivint for patients with advanced forms of blood cancer. The trial will test cirtuvivint by itself in patients whose cancer has returned or resisted treatment, and also test it combined with an existing …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
Scientists test new drug duo to target Tough-to-Treat gynecologic cancers
Disease control Recruiting nowThis early-stage study is testing a new combination of two oral drugs, M1774 and ZEN-3694, for women with recurrent ovarian or endometrial cancer. The main goals are to find the safest and most effective dose and to see how well the drugs work together to stop cancer cell growth.…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New hope for young leukemia patients: major trial tests powerful drug combo
Disease control Recruiting nowThis international Phase 3 trial is testing whether adding an immunotherapy drug called blinatumomab to standard chemotherapy and targeted drugs works better for young people (under 25) with specific, hard-to-treat types of B-cell acute lymphoblastic leukemia. The goal is to impr…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
Broccoli pill trial aims to help smokers detox
Disease control Recruiting nowThis study is testing whether a daily supplement made from broccoli seeds and sprouts can help the bodies of heavy smokers break down and remove cancer-causing chemicals from tobacco. Researchers will enroll 135 current smokers and randomly give them either the broccoli extract o…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
Double-Punch CAR-T trial offers hope for kids with Tough-to-Treat leukemia
Disease control Recruiting nowThis study is testing a new, experimental CAR-T cell therapy designed to fight two targets (CD19 and CD22) on cancer cells at once. It is for children and young adults (ages 3-39) whose B-cell leukemia or lymphoma has come back or hasn't responded to standard treatments. Doctors …
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New hope for Tough-to-Treat lymphoma: adding a pill to standard chemo
Disease control Recruiting nowThis study is testing if adding a pill called acalabrutinib to standard chemotherapy can help more people with an aggressive type of blood cancer called diffuse large B-cell lymphoma (DLBCL). It is for adults who have not yet started any treatment for their lymphoma. Researchers …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New hope for deadly brain cancer: Two-Drug combo takes on standard chemo
Disease control Recruiting nowThis study is testing whether a new combination of two immunotherapy drugs (relatlimab and nivolumab) works better and is safer than the standard chemotherapy (lomustine) for glioblastoma that has returned after initial treatment. The trial will involve about 184 adults whose bra…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New Two-Drug attack tested for Tough-to-Treat bladder cancer
Disease control Recruiting nowThis study is for people with advanced bladder cancer that has spread and has stopped responding to a common type of immunotherapy. It compares a new two-drug combination (pembrolizumab and sacituzumab govitecan) against standard chemotherapy. The goal is to see if the new combin…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New hope for rare abdominal cancer: adding immune boost to standard treatment
Disease control Recruiting nowThis study is testing if adding an immunotherapy drug (atezolizumab) to standard chemotherapy works better for controlling peritoneal mesothelioma, a rare cancer in the abdomen's lining. It will involve about 66 newly diagnosed patients who will be randomly assigned to receive ei…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
Scientists reprogram Patient's own cells to hunt deadly cancers
Disease control Recruiting nowThis trial is testing a new type of gene therapy for people with advanced pancreatic, colon, and other cancers that have a specific genetic change called KRAS G12V. Doctors take a patient's own immune cells, genetically modify them in a lab to better recognize and attack cancer c…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New tests aim to predict leukemia relapse after groundbreaking CAR-T therapy
Disease control Recruiting nowThis study is testing whether a series of advanced blood and bone marrow tests can help doctors better monitor children and young adults with a type of leukemia (B-ALL) who have recently received CAR-T cell therapy. The goal is to see if these tests can identify who is at high ri…
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
New hope for young cancer patients: testing a powerful drug combo
Disease control Recruiting nowThis study is testing whether adding an immunotherapy drug called nivolumab to standard chemotherapy works better for young people (up to age 21) newly diagnosed with nasopharyngeal cancer. The goal is to see if this combination is safe and can better control the cancer before pa…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
Targeted Triple-Drug combo tested in fight against aggressive leukemia
Disease control Recruiting nowThis study is for older adults (or younger adults unfit for standard chemo) newly diagnosed with a specific type of acute myeloid leukemia (AML) caused by a change in the IDH2 gene. It compares two oral drug combinations to see if adding a third drug, enasidenib, helps more patie…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New hope for kids with rare, recurrent blood cell disorder
Disease control Recruiting nowThis study is testing an oral medication called tovorafenib (DAY101) in children and young adults with Langerhans cell histiocytosis (LCH) that has come back or hasn't responded to previous treatments. LCH is a rare disorder where too many immune cells build up and can damage bon…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New pill aims to switch off cancer genes in advanced tumors
Disease control Recruiting nowThis early-stage trial is testing a new oral drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatments. The main goal is to find a safe dose and see how well the body handles the drug. Researchers hope the medication can turn back on ce…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New hope for tough brain cancer: trial tests powerful drug cocktail
Disease control Recruiting nowThis study is testing a new combination of drugs for a rare and aggressive brain cancer called primary central nervous system lymphoma. The main goal is to find the safest and most effective dose of a targeted drug called ibrutinib when given with a specific chemotherapy regimen.…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New hope for rare cancer: Two-Drug attack on tough sarcoma
Disease control Recruiting nowThis study is testing if a combination of two drugs, atezolizumab and selinexor, can shrink tumors in patients with advanced alveolar soft part sarcoma, a rare and difficult-to-treat cancer. The trial is for patients whose cancer has continued to grow despite prior immunotherapy.…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
Major cancer trial tests new drug combo to fight aggressive leukemia
Disease control Recruiting nowThis study is for adults newly diagnosed with a specific, aggressive type of blood cancer called BCR-ABL-positive acute lymphoblastic leukemia (ALL). It aims to see if adding a newer immunotherapy drug called blinatumomab to the standard treatment (steroids, a targeted pill, and …
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
Two-Pronged attack on rare, tough cancer
Disease control Recruiting nowThis study is for people with advanced adrenocortical cancer, a rare and aggressive cancer of the adrenal gland. It aims to see if combining a targeted drug (cabozantinib) with an immunotherapy drug (cemiplimab) works better to control the cancer and keep it from growing than the…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
Scientists test Two-Pronged attack on Tough-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing a new combination of two drugs, peposertib and liposomal doxorubicin, for people with advanced soft tissue sarcomas that have spread or cannot be removed by surgery. The main goal is to find the safest and most effective dose of this drug pair. R…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
New hope for advanced skin cancer: boosting immune system before surgery
Disease control Recruiting nowThis large, late-stage trial is testing if adding an immunotherapy drug (cemiplimab) before and after surgery works better than surgery alone for people with advanced, operable skin cancer. The goal is to see if this approach helps the body's immune system fight the cancer, reduc…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
New hope for Tough-to-Treat lung cancer: scientists test powerful drug duo
Disease control Recruiting nowThis study is testing whether combining two targeted cancer drugs is safe and effective for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The trial is for patients whose cancer has continued to grow despite previous treatment…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
New hope for rare immune disorder: can a transplant reset the Body's defenses?
Disease control Recruiting nowThis study is testing whether a stem cell transplant from a matched donor can treat GATA2 deficiency, a rare genetic disorder that causes serious infections and can lead to blood cancers. The transplant aims to replace the patient's faulty bone marrow with healthy donor cells to …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
Custom-Made vaccine fights back against tough uterine cancer
Disease control Recruiting nowThis study is testing a four-part treatment for advanced endometrial cancer that has come back or worsened after prior therapy. It combines a personalized vaccine made from a patient's own blood cells with three drugs designed to help the immune system attack the cancer. The goal…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC
-
New shot vs. old drug: battle for better skin cancer control in vulnerable patients
Disease control Recruiting nowThis study is for people with a weakened immune system who have advanced skin cancer (squamous cell carcinoma) that has returned or spread. It compares a newer treatment given as an injection (amivantamab) against a standard treatment given by IV (cetuximab). The goal is to see w…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC
-
Race to find better treatment for aggressive blood cancer
Disease control Recruiting nowThis study is testing five different drug combinations to see which works best for adults under 60 with high-risk acute myeloid leukemia (AML), a fast-growing blood cancer that's hard to treat. Participants are randomly assigned to receive either the standard chemotherapy or one …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC
-
Double attack on rare cancer: can new drug combo stop deadly Melanoma's return?
Disease control Recruiting nowThis trial is for people with mucosal melanoma, a rare and aggressive cancer, that has been surgically removed. It tests whether adding a pill called cabozantinib to an immunotherapy drug (nivolumab) is better at preventing the cancer from returning than the immunotherapy alone. …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 18, 2026 14:55 UTC
-
New Two-Pronged attack tested for Tough-to-Treat adult leukemia
Disease control Recruiting nowThis study is testing a two-step treatment for a type of blood cancer called B-cell acute lymphoblastic leukemia (ALL). It is for older adults newly diagnosed or adults whose cancer has returned or not responded to prior treatment. The approach uses two targeted drugs, inotuzumab…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
New drug duo aims to outsmart returning blood cancer
Disease control Recruiting nowThis study is testing if a combination of two oral drugs, encorafenib and binimetinib, works better than a previous single drug for adults with hairy cell leukemia that has a specific genetic change (BRAF V600 mutation) and has come back or stopped responding to standard treatmen…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
Scientists reprogram Patients' own cells to hunt their cancer
Disease control Recruiting nowThis study is testing a personalized cell therapy for people with metastatic cancer that has not responded to standard treatments. Doctors take a patient's own white blood cells, genetically modify them in a lab to better recognize and attack their specific cancer, and then infus…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
Scientists test aggressive new cocktail against rare brain cancer
Disease control Recruiting nowThis early-stage trial is testing the safety and best dose of a new four-drug combination for primary central nervous system (CNS) lymphoma, a rare cancer of the brain or spinal cord. The study combines standard chemotherapy drugs with two newer agents—one that helps the immune s…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
New 5-Drug attack on Tough-to-Treat blood cancers
Disease control Recruiting nowThis study is testing a combination of five medications (called ViPOR) for people with aggressive types of B-cell lymphoma that have returned after treatment or did not respond to prior therapy. The goal is to see if this drug combination can effectively control the cancer and le…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
New hope for Tough-to-Treat head & neck cancers
Disease control Recruiting nowThis study is for people whose head and neck cancer has come back or never fully went away after initial treatment. It tests whether adding a short course of chemotherapy or chemotherapy plus an immunotherapy drug before a second surgery is better than surgery alone. The goal is …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 18, 2026 14:40 UTC
-
Early trial tests common cancer drug for rare bleeding disorder
Disease control Recruiting nowThis early-stage study is testing whether a drug called imatinib, already used for some cancers, can help people with a specific inherited gene change (RUNX1 mutation). People with this mutation often bruise or bleed easily and have a higher lifetime risk of blood cancers. The ma…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC
-
New hope for younger AML patients: study tests powerful drug combos
Disease control Recruiting nowThis study is for younger adults (18-59) newly diagnosed with a specific intermediate-risk type of acute myeloid leukemia (AML), a blood and bone marrow cancer. It compares three different drug combinations to see if adding a newer drug called venetoclax to standard chemotherapy …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC
-
Your genes could dictate your cancer drug dose
Disease control Recruiting nowThis study is testing whether adjusting the dose of a cancer drug (belinostat) based on a patient's specific genetics can make treatment safer and more effective. It is for adults with aggressive neuroendocrine cancers. Participants receive a combination of three drugs, with the …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC
-
New hope for Tough-to-Treat head and neck cancers: can a drug duo outperform the standard?
Disease control Recruiting nowThis study is for people with advanced head and neck cancer that has returned or spread and has stopped responding to standard platinum-based chemotherapy. It aims to see if combining two immunotherapy drugs (pembrolizumab and cetuximab) helps patients live longer than using pemb…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC
-
Scientists test novel drug duo to halt advanced cancers
Disease control Recruiting nowThis early-stage trial is testing a new combination of two oral drugs, peposertib and tuvusertib, in adults with advanced solid tumors that have spread and stopped responding to standard treatments. The main goals are to find the safest and most effective dose of the drug pair an…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC
-
New hope for kids with tough cancers: early trial tests promising drug
Disease control Recruiting nowThis early-stage study is testing a drug called TURALIO in children and young adults (ages 3-35) whose cancers have returned or not responded to standard treatments. The main goals are to find the highest safe dose of the drug and understand its side effects. Participants will ta…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC
-
Scientists test 'Living Drug' combo to target common cancer driver
Disease control Recruiting nowThis early-stage trial is testing a two-part personalized treatment for adults with advanced solid cancers that have spread and contain specific KRAS gene mutations. Doctors take a patient's own immune cells, genetically modify them in a lab to recognize and attack cancer cells w…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC
-
Breast cancer pill tested against rare skin cancer
Disease control Recruiting nowThis study is testing if a drug called abemaciclib, currently used for breast cancer, can safely treat Kaposi Sarcoma (KS), a skin cancer often linked to HIV. Researchers want to find the right dose and see if it can shrink KS lesions. The trial is open to adults with KS, whether…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC
-
Double-Duty treatment trial aims to extend lives of vulnerable seniors with lung cancer
Disease control Recruiting nowThis study is for adults 70 and older with advanced non-small cell lung cancer. It compares two treatment approaches: immunotherapy alone versus immunotherapy combined with chemotherapy. The main goal is to see if the combination helps patients live longer and better control thei…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 16, 2026 15:24 UTC
-
First human test for promising new cancer pill
Disease control Recruiting nowThis is an early safety study for a new drug called TAK-243 in adults with advanced solid tumors or lymphoma. The main goal is to find the safest dose and understand the side effects. Researchers will give the drug to about 95 patients and closely monitor how their bodies handle …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 16, 2026 15:23 UTC
-
Breakthrough trial aims to outsmart aggressive uterine cancer
Disease control Recruiting nowThis study is testing if adding newer, faster-to-administer targeted drugs to standard chemotherapy works better for people with a specific type of advanced uterine cancer (HER2-positive). It will involve 360 participants who have not had prior chemotherapy. The main goal is to s…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 13, 2026 15:05 UTC
-
New hope for rare, Fast-Moving bladder cancer
Disease control Recruiting nowThis study is testing whether two existing cancer drugs, lurbinectedin and avelumab, can help control a rare and aggressive type of bladder cancer called small cell carcinoma. It is for adults whose cancer has returned and spread after their first treatment. The goal is to see if…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 12, 2026 13:52 UTC
-
New drug combo tested for Tough-to-Treat amyloidosis
Disease control Recruiting nowThis early-phase study is testing the safety and best dose of a three-drug combination (venetoclax, ixazomib, and dexamethasone) for adults with light chain amyloidosis that has returned or stopped responding to prior treatments. The study is specifically for patients who have a …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 12, 2026 13:51 UTC
-
New hope for tough brain tumors: trial targets key cancer genes
Disease control Recruiting nowThis study is testing a new drug called PLX038 for adults with aggressive brain or spinal cord tumors that have returned or progressed. It focuses on tumors with specific genetic changes (MYC or MYCN) that drive cancer growth. The goal is to find a safe dose and see if the drug c…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 12, 2026 13:51 UTC
-
Scientists test new pill to boost power of standard colon cancer treatment
Disease control Recruiting nowThis early-stage trial is testing the safety and best dose of a new oral drug, CA-4948, when added to a standard chemotherapy regimen for people with advanced colorectal cancer that has spread. The main goal is to see if the combination is safe and tolerable for patients. Researc…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 11, 2026 14:54 UTC
-
New hope for Tough-to-Treat colon cancer patients
Disease control Recruiting nowThis early-stage study is testing whether adding an experimental drug called ZEN003694 to two existing cancer drugs (cetuximab and encorafenib) is safe and effective for people with advanced colorectal cancer that has stopped responding to previous treatments. The trial will enro…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 11, 2026 14:54 UTC
-
New hope for Tough-to-Treat gynecologic cancers
Disease control Recruiting nowThis early-stage study is testing a new combination of two drugs, pelcitoclax and cobimetinib, for women with ovarian or endometrial cancer that has returned after prior treatment. The main goals are to find the safest and most effective dose and to check for side effects. Resear…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 11, 2026 14:53 UTC
-
New Bladder-Sparing cancer fight: immune drug challenges chemo
Disease control Recruiting nowThis study is for people with a specific type of high-grade bladder cancer that has not spread into the muscle wall. It compares two different treatment combinations, both given with radiation therapy. One group gets a standard chemotherapy drug, while the other gets an immunothe…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 11, 2026 14:53 UTC
-
AI hunts for hidden drug matches in tough breast cancers
Disease control Recruiting nowThis study is testing whether a computer algorithm called ENLIGHT can find better treatment options for people with aggressive, metastatic breast cancer that has stopped responding to standard therapies. Researchers will analyze a tumor sample from each participant using the algo…
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 11, 2026 14:53 UTC
-
Three-Pronged attack on tough kidney cancers
Disease control Recruiting nowThis study is testing a combination of three drugs—bevacizumab, erlotinib, and atezolizumab—to see if they can control or shrink advanced kidney cancers linked to a hereditary condition (HLRCC) or a specific type called papillary renal cell cancer. The trial aims to enroll 65 pat…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 10, 2026 12:54 UTC
-
Radioactive 'Tumor-Seeker' drug tested for Tough-to-Treat prostate cancer
Disease control Recruiting nowThis study is testing an experimental radioactive drug called lutetium Lu 177 dotatate for men with an aggressive form of prostate cancer that has spread and developed neuroendocrine features. The drug is designed to find and deliver radiation directly to cancer cells. The main g…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 10, 2026 12:53 UTC
-
New hope for kids with devastating brain cancers: testing a novel drug combo
Disease control Recruiting nowThis study is testing whether adding a new oral drug called selinexor to standard radiation therapy is safe and effective for children and young adults with newly diagnosed, aggressive brain tumors (DIPG or high-grade glioma). The first part of the trial aims to find the safest d…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 10, 2026 12:52 UTC
-
Scientists re-engineer Patient's own cells to fight multiple cancers
Disease control Recruiting nowThis study is testing a new type of personalized cancer treatment called CAR-T cell therapy. Doctors take a patient's own immune cells, genetically modify them in a lab to better recognize and attack cancer cells that have a specific marker called CD70, and then infuse them back …
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 09, 2026 14:24 UTC
-
New pill aims to boost power of CAR-T cancer treatment
Disease control Recruiting nowThis study is testing if taking a daily pill called iberdomide can help patients with multiple myeloma live longer without their cancer getting worse after they receive a powerful one-time treatment called CAR-T cell therapy. Currently, doctors just monitor patients after CAR-T t…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 06, 2026 15:38 UTC
-
Radioactive 'Smart Bomb' drug trial seeks to shrink tough cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug that delivers radiation directly to cancer cells in people with advanced tumors that have spread and cannot be removed by surgery. The treatment targets a specific protein found on several cancer types, including some lung, kidney, hea…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 03, 2026 14:06 UTC
-
New drug trial aims to supercharge immune system against prostate cancer
Disease control Recruiting nowThis study is testing whether adding a new immune-boosting drug called M9241 to standard radiation and hormone therapy can help the body's own defenses fight prostate cancer better. It will involve about 65 men with high- or intermediate-risk prostate cancer that hasn't spread. T…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 02, 2026 15:26 UTC
-
Scientists target genetic flaw in relapsed blood cancer with new pill combo
Disease control Recruiting nowThis study is testing a new combination of two oral drugs, mirdametinib and sirolimus, for adults with advanced multiple myeloma that has returned or stopped responding to other treatments. The trial aims to find a safe dose and see if the drugs can help control the cancer in pat…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 02, 2026 15:24 UTC
-
Cancer trial matches patients to targeted drugs based on tumor markers
Disease control Recruiting nowThis study aims to see if matching patients to one of three targeted cancer drugs works better for treating advanced solid tumors. It will enroll 500 adults whose cancer has spread and who have specific proteins (Trop-2, nectin-4, or HER2) in their tumor. Patients will first be s…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Feb 27, 2026 15:19 UTC
-
Scientists test new drug duo to attack advanced cancers
Disease control Recruiting nowThis early-phase trial is testing a new combination of two drugs, temozolomide and M1774, for people with advanced cancers that have spread. The main goals are to find the safest and most effective dose and to see if the combination can shrink or stabilize tumors, especially in a…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Feb 25, 2026 15:07 UTC
-
One blood draw could screen for 11 cancers
Diagnosis Recruiting nowThis study is testing two new blood tests designed to screen for 11 different cancers at the same time. It will enroll 24,000 healthy adults aged 45-75 to see how well these tests work for early detection and to understand how people and their doctors respond to the results. The …
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Mar 30, 2026 14:34 UTC
-
Could a new scan spot returning cancer sooner?
Diagnosis Recruiting nowThis study is testing if a new type of imaging scan can better detect multiple myeloma, a blood cancer, compared to the scan currently used. Researchers want to see if this new scan can find returning disease earlier, which could help doctors start treatment sooner. About 60 adul…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Mar 27, 2026 12:40 UTC
-
New scan could spot hidden cancers more clearly
Diagnosis Recruiting nowThis study is testing a new imaging substance called [18F]FAPI-74 to see if it can detect certain cancers better than current standard scans. It will involve 320 adults with one of 10 specific cancer types who are scheduled for treatment. Participants will receive both the new tr…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Mar 23, 2026 15:18 UTC
-
Could a simple At-Home swab replace the Doctor's office for cervical cancer screening?
Diagnosis Recruiting nowThis study is testing whether people can collect their own vaginal samples at home for HPV testing, which could make cervical cancer screening easier and more accessible. Researchers will compare the accuracy of these self-collected samples to samples collected by a doctor during…
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Mar 18, 2026 14:41 UTC
-
New scan aims to pinpoint rogue Hormone-Producing tumors
Diagnosis Recruiting nowThis study is testing a new radioactive tracer called [68Ga]Ga-PentixaFor to see if it can make PET scans better at identifying adrenal tumors that are overproducing hormones. Researchers will give the tracer to 80 adults with conditions like hyperaldosteronism or Cushing's syndr…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Mar 11, 2026 14:54 UTC
-
Personalized pill dose could sharply cut breast cancer risk
Prevention Recruiting nowThis study is testing a personalized approach to using the drug tamoxifen to prevent breast cancer in premenopausal women at higher-than-average risk. Researchers want to see if starting with a low dose and increasing it only for women who don't show a good initial response on th…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Apr 01, 2026 14:42 UTC
-
First human trial launches for drug aimed at stopping colon cancer before it starts
Prevention Recruiting nowThis early-stage study is testing a drug called ONC201 (dordaviprone) to see if it is safe and can help prevent colorectal cancer. It is for adults who have a high risk of developing colon cancer due to a condition called Familial Adenomatous Polyposis (FAP) or a history of many …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Apr 01, 2026 14:41 UTC
-
New hope for women at high risk of breast cancer: study tests two preventive drugs
Prevention Recruiting nowThis study is testing two drugs, acolbifene and a low dose of tamoxifen, to see which is better at preventing breast cancer in premenopausal women who are at high risk. It will involve 80 women who will take one of the drugs daily for six months. Researchers will check for change…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Mar 30, 2026 14:32 UTC
-
New drug trial aims to stop Pre-Cancerous condition from turning deadly
Prevention Recruiting nowThis study is testing if a drug called obeticholic acid can prevent Barrett's esophagus, a condition that can lead to esophageal cancer, from getting worse. Researchers will give the drug or a placebo (inactive pill) to 30 adults with Barrett's esophagus for six months. They want…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Mar 27, 2026 12:39 UTC
-
Can a pill and fish oil stop breast cancer before it starts?
Prevention Recruiting nowThis study is testing whether a low dose of the drug tamoxifen, taken with or without high-dose omega-3 fish oil supplements, can help prevent breast cancer in women at high risk. It is for overweight or obese postmenopausal women who have specific risk factors, like a family his…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Mar 25, 2026 14:07 UTC
-
Zap away the leak? new device aims to help men after prostate cancer
Symptom relief Recruiting nowThis study is testing whether a home-use electrical stimulation device can help reduce urinary incontinence in men who have been treated for prostate cancer. Participants will use the device at home for 20 minutes a day, five days a week, for six weeks. The main goal is to see if…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Symptom relief
Last updated Apr 01, 2026 14:41 UTC
-
Virtual therapy trial offers hope for stressed parents of children with rare diseases
Symptom relief Recruiting nowThis study is testing if a type of therapy called Acceptance and Commitment Therapy (ACT) can help parents and guardians better manage the stress of caring for a child with a rare genetic condition known as a RASopathy. The 8-week program is done completely from home using a smar…
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Symptom relief
Last updated Mar 31, 2026 12:11 UTC
-
Can a week at camp heal the mind of a child with cancer?
Symptom relief Recruiting nowThis study is exploring whether a special, week-long camping experience can improve the psychological well-being of children and young adults with cancer. Researchers will observe and interview up to 5,000 participants to see if the camp boosts self-esteem and improves family and…
Sponsor: National Cancer Institute (NCI) • Aim: Symptom relief
Last updated Mar 30, 2026 14:28 UTC
-
Scientists seek blood samples to unlock Leukemia's secrets
Knowledge-focused Recruiting nowThis study aims to collect blood, urine, and tissue samples from adults with certain blood cancers and from healthy volunteers. The goal is to study these samples in a lab to better understand diseases like hairy cell leukemia and to help develop future treatments. No treatment i…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:43 UTC
-
Massive 10,000-Man study aims to decode prostate cancer scans
Knowledge-focused Recruiting nowThis study aims to collect detailed medical and imaging data from 10,000 men with or at risk for prostate cancer. Researchers will analyze this information over at least five years to understand how different scan results relate to a patient's disease and outcomes. The goal is to…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:43 UTC
-
Landmark study tracks cancer risk in rare genetic blood disorders
Knowledge-focused Recruiting nowThis study aims to understand why people with inherited bone marrow failure syndromes have a higher risk of developing cancer. Researchers will follow 4,000 participants, including patients with these rare genetic conditions and their family members, to track cancer rates and ide…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:43 UTC
-
Scientists hunt for early warning signs in brain cancer Patients' blood
Knowledge-focused Recruiting nowThis study aims to find out if measuring certain proteins in the blood and urine of patients with a serious brain tumor (glioblastoma) can help predict if the cancer will come back within a year after radiation treatment. Researchers will collect samples from about 200 adults bef…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:42 UTC
-
Scientists hunt for DNA clues to Chemo's painful side effect
Knowledge-focused Recruiting nowThis study aims to understand why some breast cancer patients develop nerve damage (peripheral neuropathy) from the chemotherapy drug paclitaxel, while others do not. Researchers will analyze the stored DNA of 575 patients who previously received this treatment. By looking for ge…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:42 UTC
-
Scientists gather prostate cancer clues from 3,000 men
Knowledge-focused Recruiting nowThis study aims to collect blood, urine, saliva, and tissue samples from men with prostate cancer to understand the genetic and cellular changes that cause the disease. Researchers will analyze these samples to learn how prostate cancer develops and progresses, which could lead t…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:42 UTC
-
Scientists hunt for genetic clues to cancer drug side effect
Knowledge-focused Recruiting nowThis study aims to understand why some breast cancer patients develop severe high blood pressure when taking the drug bevacizumab. Researchers will analyze the DNA of about 350 patients who either did or did not experience this side effect. The goal is to find genetic markers tha…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:42 UTC
-
Scientists hunt for the genetic roots of a rare, inherited cancer
Knowledge-focused Recruiting nowThis study aims to understand the genetic causes of a rare, inherited condition called Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC). Researchers are recruiting families affected by HLRCC to learn which gene changes cause the disease and how it leads to kidney tumors, skin …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:42 UTC
-
Scientists watch cancer evolve in real time
Knowledge-focused Recruiting nowThis study aims to understand how follicular lymphoma, a type of blood cancer, naturally changes and progresses over time. Researchers will closely monitor 200 adults who have been diagnosed but have not yet started any treatment. By collecting blood, tissue, and scan data regula…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:41 UTC
-
Advanced scans aim to solve why some prostate cancers resist radiation
Knowledge-focused Recruiting nowThis study aims to better understand why some prostate cancers return after radiation treatment. Researchers will use detailed MRI scans and biopsies to closely examine the prostate before and after radiation therapy. The goal is to improve the detection of cancer recurrence and …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:41 UTC
-
Scientists gather cells in hunt for future gene therapy cures
Knowledge-focused Recruiting nowThis study aims to collect special blood stem cells from adults with specific, rare immune system diseases. The cells are taken to a laboratory to test if scientists can fix their genetic defects. No treatment or therapy is given to participants as part of this study; it is purel…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:41 UTC
-
Patients help design tools to measure how NF1 tumors affect appearance
Knowledge-focused Recruiting nowThis study aims to create better questionnaires to understand how visible tumors affect the appearance and daily life of people with Neurofibromatosis Type 1 (NF1). Researchers are asking 110 patients and caregivers to review and discuss draft questionnaires in focus groups. The …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:12 UTC
-
Scientists seek cancer patients to donate blood and tissue for research
Knowledge-focused Recruiting nowThis study aims to collect blood, tumor tissue, and stool samples from people diagnosed with gastrointestinal cancers. Researchers will use these samples to study how the patient's immune system responds to the cancer and how gut bacteria might influence the disease. No treatment…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:12 UTC
-
Scientists hunt for hidden cancers in High-Risk families
Knowledge-focused Recruiting nowThis study aims to learn if advanced imaging scans, blood tests, and minor surgical procedures can help detect mesothelioma and other cancers earlier in people who carry an inherited BAP1 gene mutation. Researchers will follow 800 adults age 30+ with this mutation, performing ann…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:11 UTC
-
Scientists track rare pancreatic tumors to find better detection methods
Knowledge-focused Recruiting nowThis study aims to understand how pancreatic tumors develop in people with von Hippel-Lindau (VHL) disease, a rare genetic condition. Researchers will follow 740 participants aged 12 and older over many years, using regular scans and tests to track tumor growth. The study will te…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:11 UTC
-
New surgical tool aims to give doctors a clearer picture of bladder cancer
Knowledge-focused Recruiting nowThis study is testing a modified surgical tool to see if it can provide better information about bladder cancer tumors. Researchers will use the tool on bladders that have already been surgically removed from patients for medical reasons. The goal is to see if this new method of …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:11 UTC
-
Scientists track families for decades to unlock Cancer's genetic secrets
Knowledge-focused Recruiting nowThis study aims to understand why some people and families develop rare or multiple cancers. Researchers will observe 500 participants, including those with unusual cancers or a strong family history, to learn how genes and environmental factors work together. The study involves …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:11 UTC
-
Scientists track rare cancer syndrome over years to find better treatments
Knowledge-focused Recruiting nowThis study aims to understand how medullary thyroid cancer and the related MEN2 genetic syndrome develop and change over time in children and adults. Researchers will observe 259 participants who have the condition, tracking their health through regular check-ups, scans, and bloo…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:11 UTC
-
Scientists launch major study to unravel mysteries of rare 'Smell' cancer
Knowledge-focused Recruiting nowThis study aims to learn more about olfactory neuroblastoma, a rare cancer that starts in the upper nasal cavity and can affect the sense of smell. Researchers will track the health of 525 children and adults with this condition over many years, collecting medical information, sa…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:10 UTC
-
Researchers seek Patients' help to build better pain surveys for rare tumor disorder
Knowledge-focused Recruiting nowThis study aims to create and test better questionnaires for people with neurofibromatosis 1 (NF1) who have painful plexiform tumors. Researchers are working with patients and parents to improve how pain and its impact on daily life are measured. The goal is to develop reliable t…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:35 UTC
-
Scientists gather clues in fight against bladder cancer
Knowledge-focused Recruiting nowThis study aims to collect blood, urine, saliva, and tissue samples from people with bladder or urinary tract cancer, as well as from healthy volunteers. Researchers will compare these samples to learn what genetic and cellular changes cause this cancer to develop. The goal is to…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:35 UTC
-
Scientists launch 20-Year quest to unlock secrets of rare blood disorder
Knowledge-focused Recruiting nowThis study aims to learn more about myelodysplastic syndromes (MDS), a group of rare blood disorders, by observing how the disease naturally progresses over a very long time. Researchers will enroll about 1,100 people, including those with MDS and healthy donors, to collect blood…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:34 UTC
-
Scientists track genetic changes to make cancer drugs safer after transplants
Knowledge-focused Recruiting nowThis study aims to understand how stem cell transplants affect how patients process medications. Researchers will collect DNA samples from adults with blood cancers before and after transplant to determine the best source for genetic testing. The goal is to improve medication dos…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:34 UTC
-
Scientists gather cancer clues to build future cures
Knowledge-focused Recruiting nowThis study collects blood, tissue, and other samples from adults with cancer or pre-cancerous conditions. The goal is to understand how cancer works and why treatments affect people differently. Researchers will bank these samples for future lab studies to help develop better imm…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:34 UTC
-
Healthy volunteers give cells to fuel cancer research breakthroughs
Knowledge-focused Recruiting nowThis study collects white blood cells from healthy volunteers to help researchers develop and improve new cancer treatments. The donated cells are used in the lab to grow cancer-fighting immune cells from patients, a process needed for advanced therapies. Healthy adults can donat…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:33 UTC
-
Scientists track families with rare cancer gene to unlock disease secrets
Knowledge-focused Recruiting nowThis study aims to understand how cancer develops in people who are born with specific gene mutations, like the BAP1 gene, which is linked to mesothelioma and other cancers. Researchers will follow 1,000 participants, including people with mesothelioma and their family members wh…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:32 UTC
-
Decade-Long hunt for cancer clues in rare genetic disorder
Knowledge-focused Recruiting nowThis study aims to understand how and why people with Fanconi anemia develop certain cancers, particularly in the mouth, throat, and genital areas. Researchers will regularly screen 200 participants aged 8 and older over 10 years to track early warning signs and disease progressi…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:31 UTC
-
Major study aims to unlock secrets of serious transplant complication
Knowledge-focused Recruiting nowThis study aims to learn more about chronic graft-versus-host disease (cGVHD), a serious and complex condition that can occur after a stem cell transplant. Researchers will observe about 650 patients, including some who have had transplants but do not have cGVHD, to identify mark…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:31 UTC
-
Massive 10,000-Person hunt for clues to beat rare cancers
Knowledge-focused Recruiting nowThis study aims to learn more about rare cancers by collecting health information and biological samples from people who have them or are at risk. Researchers will follow 10,000 participants over time to understand how these rare tumors develop and behave. The goal is to use this…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:30 UTC
-
Scientists hunt for clues to make liver cancer immunotherapy work for more patients
Knowledge-focused Recruiting nowThis study aims to understand why some liver cancer patients respond to immunotherapy while others do not. Researchers will collect blood, tissue, and health data from 500 adults with liver cancer who have had or will have immunotherapy. By analyzing this information over time, t…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:30 UTC
-
Scientists seek cancer clues in patient samples
Knowledge-focused Recruiting nowThis study aims to collect blood, tissue, and fluid samples from adults with lymphoma, multiple myeloma, or related blood cancers. The goal is to help researchers better understand the biology of these diseases in the lab. This is a sample collection study only and does not provi…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:29 UTC
-
Scientists track nerve tumors for a decade to spot cancer early
Knowledge-focused Recruiting nowThis study aims to learn how to better predict which benign nerve tumors in people with Neurofibromatosis type 1 (NF1) might become cancerous. Researchers will observe 225 participants, aged 3 and up, for 10 years, using scans and check-ups to track their tumors. Participants wil…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:29 UTC
-
Landmark study hunts clues in rare urinary cancers
Knowledge-focused Recruiting nowThis study aims to understand the course of rare cancers in the urinary system (like bladder, kidney, and prostate cancers) by tracking patients over time. Researchers will collect medical information, blood, urine, and sometimes tumor samples from about 1,100 adults with these c…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:29 UTC
-
Scientists seek healthy volunteers to donate samples in 50-Year quest to understand blood cancer
Knowledge-focused Recruiting nowThis study aims to collect blood, bone marrow, skin, saliva, and stool samples from 1,000 healthy adults. Researchers will use these samples as a 'healthy comparison' to better understand myelodysplastic syndromes (MDS), a type of blood cancer. The goal is to build a database tha…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:28 UTC
-
Scientists gather cancer clues from 2000 patients to crack deadly disease code
Knowledge-focused Recruiting nowThis study aims to collect tissue samples from adults with various lung and thymic cancers to better understand these diseases. Researchers will analyze blood, tumor, and other samples from up to 2000 participants to learn how these cancers develop and respond to treatment. The g…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:28 UTC
-
Scientists seek blood clues to prostate Cancer's deadly turn
Knowledge-focused Recruiting nowThis study aims to understand why some prostate cancers stop responding to standard treatments by collecting blood samples from patients. Researchers will analyze the genetic material in the blood to look for differences that might explain why the disease becomes more aggressive …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:27 UTC
-
Scientists track 2,000 men to crack prostate Cancer's genetic code
Knowledge-focused Recruiting nowThis study aims to understand how specific gene mutations affect the course of prostate cancer over a person's lifetime. Researchers will follow 2,000 men who have prostate cancer and certain gene changes to see how their disease progresses and responds to treatments. The goal is…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:27 UTC
-
Scientists track High-Risk men to unlock prostate cancer secrets
Knowledge-focused Recruiting nowThis study aims to learn more about which men with specific inherited genetic changes are most likely to develop prostate cancer. Researchers will follow 500 men, aged 30-75, who have these genetic changes but do not have prostate cancer. Participants will have regular health che…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:40 UTC
-
National cancer institute launches massive 'Matchmaking' trial for leukemia patients
Knowledge-focused Recruiting nowThis study is a large screening program designed to help match adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to the most appropriate treatment study within the national MyeloMATCH network. It involves testing a patient's bone marrow and blood for spec…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:40 UTC
-
Massive 200,000-Person study launches to unlock Cancer's secrets
Knowledge-focused Recruiting nowThis long-term study aims to understand what causes cancer by tracking 200,000 healthy adults aged 30-70. Participants will regularly complete health surveys, donate blood and saliva samples, and share their electronic health records over many years. Researchers will analyze this…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:39 UTC
-
Kids get their say: new survey aims to capture true toll of transplant side effect
Knowledge-focused Recruiting nowThis study aims to create and test a new questionnaire specifically for children and teens living with chronic graft-versus-host disease (cGVHD), a serious and often painful side effect of stem cell transplants. Researchers will work with 420 children (ages 5-17) and their parent…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:38 UTC
-
Scientists seek genetic clues to cancer drug reactions
Knowledge-focused Recruiting nowThis study aims to understand why people react differently to cancer drugs. Researchers will collect blood or cheek swab samples from about 1,100 cancer patients already enrolled in treatment trials at the National Cancer Institute. By analyzing genes, they hope to learn which ge…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:38 UTC
-
Patients donate tissue to fuel future cancer breakthroughs
Knowledge-focused Recruiting nowThis study collects tissue and fluid samples from adults and children with cancer. The goal is to gather these samples for research to help scientists better understand cancer and develop new tests and models for future treatments. Samples are collected during procedures patients…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 25, 2026 14:08 UTC
-
Massive 5,000-Person study hunts for clues in family cancer genes
Knowledge-focused Recruiting nowThis study aims to learn more about inherited kidney and urinary tract cancers by observing families who have them. Researchers will collect health information and genetic samples from up to 5,000 participants over time. The goal is to understand how these diseases develop, how t…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 25, 2026 14:07 UTC
-
Scientists track rare cancer to unlock future treatments
Knowledge-focused Recruiting nowThis study aims to better understand chordoma, a rare bone cancer, by tracking people who have it over many years. Researchers will monitor how the disease progresses, how it responds to treatments, and how it affects people's daily lives. The information gathered will help desig…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 24, 2026 12:03 UTC
-
Scientists seek Cancer's genetic blueprint in major tissue study
Knowledge-focused Recruiting nowThis study aims to collect tissue, blood, and urine samples from people with cancers of the chest (like lung, esophageal, or pleural cancers) to better understand the genetic changes in these diseases. Researchers will analyze these samples to learn how cancers develop and potent…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 24, 2026 12:02 UTC
-
Scientists track mysterious Virus-Linked illness
Knowledge-focused Recruiting nowThis study aims to understand a rare illness called KSHV Inflammatory Cytokine Syndrome (KICS), which is caused by a virus. Researchers will observe up to 140 adults who have the virus and related symptoms to learn how the disease develops and affects people over time. The goal i…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 24, 2026 12:02 UTC
-
Scientists gather tumor samples in hunt for next cancer cures
Knowledge-focused Recruiting nowThis study collects tumor and normal tissue samples from patients who are already scheduled for a biopsy or surgery for a solid tumor. The goal is to use these samples in research to discover new targets for future cancer therapies. No experimental treatments are given as part of…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 24, 2026 12:02 UTC
-
Scientists track 5,000 families to unlock secrets of rare cancer syndrome
Knowledge-focused Recruiting nowThis study aims to better understand Li-Fraumeni syndrome (LFS), a rare genetic condition that greatly increases a person's risk of developing many types of cancer. Researchers will follow 5,000 individuals and families with LFS over many years to learn about the types of cancers…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:29 UTC
-
Scientists gather cancer clues to build future cures
Knowledge-focused Recruiting nowThis study collects blood, urine, and tissue samples from people with or suspected of having cancers of the kidney, bladder, prostate, and other urinary system cancers. The samples are stored in a tissue bank and used for research to understand the genetic causes of these cancers…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:29 UTC
-
Scientists track rare childhood cancer gene through families
Knowledge-focused Recruiting nowThis study aims to learn about a rare genetic condition called DICER1 syndrome, which increases the risk for several rare cancers, especially in children. Researchers are enrolling 1,500 people who have these cancers or are close relatives, to collect family histories, medical re…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:18 UTC
-
Scientists track rare cancer for a decade to unlock its secrets
Knowledge-focused Recruiting nowThis study aims to understand how Kaposi sarcoma (KS), a cancer often linked to HIV, behaves over many years. Researchers will observe 150 adults with KS, tracking their health through regular exams, scans, and tissue samples for up to 10 years. The goal is to learn why the disea…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:17 UTC
-
AI tool races against time to find brain cancer treatments
Knowledge-focused Recruiting nowThis study is testing a new technology called SmartMatch that analyzes small pieces of surgically removed brain tumor tissue to see how they react to different drugs. Researchers want to see if this analysis can be completed and a report provided to doctors within 21 days of surg…
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:17 UTC
-
15-Year watch: scientists track Long-Term effects of cancer vaccines
Knowledge-focused Recruiting nowThis study is a long-term health check-up for people who previously received experimental cancer vaccines in other research trials. It aims to monitor their health for up to 15 years to ensure the vaccines are safe in the long run. Participants will have annual check-ups or phone…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:16 UTC
-
Scientists seek donors to unlock secrets of HIV and cancer
Knowledge-focused Recruiting nowThis study is collecting blood, bone marrow, and tissue samples from people with HIV or certain virus-related cancers. The goal is to help researchers better understand how these diseases work, which could lead to future treatments. Participants will provide samples but will not …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:15 UTC
-
MRI scans may replace some biopsies for prostate cancer Watch-and-Wait
Knowledge-focused Recruiting nowThis study is testing whether advanced MRI scans can improve how doctors monitor men with low-risk prostate cancer who are on 'active surveillance' (watchful waiting). Researchers want to see if these scans can accurately track the cancer over time and possibly reduce the need fo…
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:14 UTC
-
Scientists watch and listen to understand the hidden stress of cancer checks
Knowledge-focused Recruiting nowThis study aims to learn about the anxiety people with Fanconi anemia feel during their required cancer screenings. Researchers will observe 20 adults during their regular screening visits, taking notes on their body language, conversations, and environment. The goal is to better…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 20, 2026 14:55 UTC
-
Scientists gather cancer clues in major tissue bank
Knowledge-focused Recruiting nowThis study aims to collect blood, urine, and tumor samples from up to 1,000 patients with mesothelioma and other related cancers. The purpose is to build a tissue bank for future research to better understand these diseases. Participants will be followed over time to track their …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 20, 2026 14:47 UTC
-
Helping young patients voice their wishes before risky transplants
Knowledge-focused Recruiting nowThis study is exploring whether structured conversations about future care preferences are helpful and acceptable for young adults (ages 18-39) undergoing stem cell transplants and their caregivers. Participants will have three guided discussions over several weeks to talk about …
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 19, 2026 14:56 UTC
-
Scientists pause HIV meds to hunt hidden virus
Knowledge-focused Recruiting nowThis study aims to better understand where and how HIV hides in the body when people are on effective treatment. Researchers will compare two groups of adults with well-controlled HIV: one stays on their regular medication, while the other pauses it for up to 90 days. Using speci…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 19, 2026 14:55 UTC
-
Scientists seek tumor samples in hunt for new GIST treatments
Knowledge-focused Recruiting nowThis study aims to follow people with gastrointestinal stromal tumors (GIST) to collect their tumor tissue for laboratory research. Participants will be monitored for up to 10 years and may have surgery at the NIH if needed. The main goal is to use the collected tissue to create …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 18, 2026 14:55 UTC
-
Scientists hunt genetic clues in cancers tied to viruses and HIV
Knowledge-focused Recruiting nowThis study aims to understand the genetic makeup of cancers that occur in people with viral infections, HIV, or immune system disorders like Castleman disease. Researchers will collect and analyze tissue samples from adult participants to look for genetic changes that might expla…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 18, 2026 14:42 UTC
-
New scan aims to unlock secrets of returning prostate cancer
Knowledge-focused Recruiting nowThis study aims to understand how prostate cancer that returns after initial treatment changes over time. Researchers will use a new type of PET scan on up to 350 men to track the cancer's progression for up to five years. The goal is to gather knowledge about the disease's behav…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 18, 2026 14:41 UTC
-
Scientists seek cancer clues in patient blood samples
Knowledge-focused Recruiting nowThis study aims to collect blood and other samples from adults with cancer to help scientists better understand how cancer affects the immune system and tumor biology. Participants provide samples for lab analysis, but this is not a treatment study. The goal is to gather knowledg…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 18, 2026 14:40 UTC
-
Scientists build a living library of cancer to unlock treatment secrets
Knowledge-focused Recruiting nowThis study is collecting tissue and blood samples from cancer patients over time to create a research resource called a biobank. Researchers will analyze these samples to understand how cancer changes during treatment and why some treatments stop working. The goal is to help scie…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 17, 2026 13:09 UTC
-
Massive cancer screening aims to match patients with Cutting-Edge experimental treatments
Knowledge-focused Recruiting nowThis study screens adults with various cancers to see if they qualify for experimental treatments being tested by the National Cancer Institute's Surgery Branch. Participants undergo tests and evaluations to determine their eligibility for specific treatment trials. The study als…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 17, 2026 13:09 UTC
-
Scientists track families to unlock secrets of inherited blood cancers
Knowledge-focused Recruiting nowThis study aims to understand how inherited changes in certain genes, especially the DDX41 gene, increase a person's risk of developing blood cancers like myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Researchers will follow over 500 participants, including peo…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 17, 2026 12:55 UTC
-
Scientists hunt genetic clues to rare disease that raises cancer risk
Knowledge-focused Recruiting nowThis study aims to better understand Birt-Hogg-Dubé (BHD) syndrome, a rare inherited condition. Researchers want to learn how the gene that causes BHD increases a person's risk for developing kidney tumors, lung cysts, and skin growths. The study is enrolling about 950 people wit…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 16, 2026 15:26 UTC
-
Landmark study tracks rare cancers for life to unlock treatment secrets
Knowledge-focused Recruiting nowThis study aims to learn more about rare neuroendocrine cancers by observing people who have them over their lifetime. Researchers will collect blood, saliva, and tumor samples from up to 300 participants to understand how these cancers progress and what treatments work best. The…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 16, 2026 15:26 UTC
-
Scientists seek cancer tissue donations from dying patients to unlock disease secrets
Knowledge-focused Recruiting nowThis study aims to collect cancer tissue samples shortly after death to help researchers understand how cancers spread and become resistant to treatments. Adults with advanced lung, ovarian, bladder, or certain other cancers who are receiving end-of-life hospice care can particip…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 16, 2026 15:25 UTC
-
Scientists probe CAR T-Cell Therapy's hidden impact on young minds
Knowledge-focused Recruiting nowThis study aims to understand if CAR T-cell therapy, a powerful treatment for aggressive blood cancers, affects how children and young adults think, learn, and remember. Researchers will follow 60 participants aged 5-35 for up to 3 years, giving them regular thinking and memory t…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 16, 2026 15:24 UTC
-
Scientists hunt for skin cancer clues in High-Risk families
Knowledge-focused Recruiting nowThis study aims to understand why some families are at high risk for melanoma, a serious skin cancer. Researchers will observe 3,000 people with a personal or family history of melanoma or unusual moles. Participants will provide health information, blood or cheek cell samples, a…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 13, 2026 15:05 UTC
-
Scientists track deadly virus disease to find better treatments
Knowledge-focused Recruiting nowThis study aims to learn more about a rare and serious disease called KSHV-associated Multicentric Castleman's Disease (MCD). Researchers will observe 195 adult patients over several years to understand how the disease progresses, how patients respond to current treatments, and w…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 12, 2026 13:50 UTC
-
Scientists build massive cancer sample library to unlock disease secrets
Knowledge-focused Recruiting nowThis study aims to collect and store blood, tumor, and tissue samples from children and adults with cancer to create a large research repository. The goal is to help scientists better understand cancer biology by studying these samples in the lab. Participants provide samples onl…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 11, 2026 14:54 UTC
-
Major study launches to unlock mysteries of rare genetic syndromes and cancer link
Knowledge-focused Recruiting nowThis study aims to learn more about a group of rare genetic conditions called RASopathies. Researchers will follow 500 people with these conditions and their family members over many years to understand their health challenges, especially their risk of developing cancer. The goal…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 10, 2026 12:52 UTC
-
Eye test could reveal hidden pain in nerve disorder
Knowledge-focused Recruiting nowThis study is testing a new device to see if it can objectively measure pain and other sensory problems in people with neurofibromatosis type 1 (NF1). Researchers will use a camera to record changes in the pupil of the eye while a small, non-painful electrical signal is applied t…
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 10, 2026 12:52 UTC
-
Scientists seek clues in endocrine tumors to improve future care
Knowledge-focused Recruiting nowThis study aims to collect and analyze tissue samples from people undergoing surgery for endocrine tumors (like thyroid, adrenal, or pancreatic tumors). Researchers will study the genetic and molecular makeup of these tumors to learn how to better tell benign from cancerous growt…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 09, 2026 14:26 UTC
-
Tracking Radiation's legacy: what happens to cancer survivors years later?
Knowledge-focused Recruiting nowThis study aims to understand the long-term health effects and disease progression in people who have received radiation therapy for cancer. Researchers will collect follow-up health data from 700 adult participants who previously had radiation treatment. The goal is to learn abo…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 09, 2026 14:24 UTC
-
Tracking the Decades-Long journey after a Life-Saving transplant
Knowledge-focused Recruiting nowThis study aims to understand the long-term health of people who have received a stem cell transplant from a relative. Researchers will follow 2000 transplant recipients and their donors for many years, collecting health data and samples to learn about late complications like new…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 02, 2026 15:25 UTC